Status
Conditions
Treatments
About
The primary objective is to evaluate the Intraocular pressure reducing effect of Xalatan over 3 months. The secondary objective is to study the other efficacy parameters during treatment for 3 months
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
996 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal